Immunocytochemistry/ Immunofluorescence: CD20 Antibody (IGEL/773) [NBP2-44745] - Immunofluorescence staining of Raji cells using CD20 Antibody (IGEL/773) followed by goat anti-Mouse IgG conjugated to CF488 (green). ...read more
Immunohistochemistry-Paraffin: CD20 Antibody (IGEL/773) [NBP2-44745] - Formalin-fixed, paraffin-embedded human Lymphoma stained with CD20 Mouse Monoclonal Antibody (IGEL/773).
Flow Cytometry: CD20 Antibody (IGEL/773) [NBP2-44745] - Flow Cytometric Analysis of Raji cells. CD20 Antibody (IGEL/773) followed by goat anti-Mouse IgG-CF488 (Blue); Isotype Control (Red).
Immunohistochemistry-Paraffin: CD20 Antibody (IGEL/773) [NBP2-44745] - Human Tonsil stained with CD20 Monoclonal Antibody (IGEL/773)
Immunohistochemistry-Paraffin: CD20 Antibody (IGEL/773) [NBP2-44745] - Human Lymphoma stained with CD20 Monoclonal Antibody (IGEL/773)
Immunohistochemistry-Paraffin: CD20 Antibody (IGEL/773) [NBP2-44745] - Immunohistochemistry-Paraffin: CD20 Antibody (IGEL/773) - Azide and BSA Free [NBP2-47840] - Formalin-fixed, paraffin-embedded human Tonsil stained ...read more
Recombinant full-length human CD20 protein (Uniprot: P11836 )
Predominantly cell surface with some cytoplasmic
Recognizes a protein of 30-33kDa, which is identified as CD20. It is a non-Ig differentiation antigen of B-cells and its expression is restricted to normal and neoplastic B-cells, being absent from all other leukocytes and tissues. CD20 is expressed by pre B-cells and persists during all stages of B-cell maturation but is lost upon terminal differentiation into plasma cells. This monoclonal antibody can be used for immunophenotyping of leukemia and malignant cells, B lymphocyte detection in peripheral blood and B cell localization in tissues. It reacts with the majority of B-cells present in peripheral blood and lymphoid tissues and their derived lymphomas. In lymphoid tissue, germinal center blasts and B-immunoblasts are particularly reactive. It is a reliable antibody for ascribing a B-cell phenotype in known lymphoid tissues. Rarely, CD20-positive T-cell lymphomas have been reported. Reactivity has also been noted with Reed-Sternberg cells in cases of Hodgkin s disease, particularly of lymphocyte predominant type.
Protein A or G purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use in Multiplex Immunoassay reported in scientific literature (PMID: 31942075) Immunohistology (Formalin-fixed): 1-2ug/ml for 30 minutes at RT. Staining of formalin-fixed tissues requires boiling tissue sections in 10mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes. Optimal dilution for a specific application should be determined. Optimal dilution for a specific application should be determined.
Read Publication using NBP2-44745 in the following applications:
200ug/ml of antibody purified from Bioreactor Concentrate by Protein A or G. Prepared in 10 mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0 mg/ml. (NBP2-47840)
Antibody with azide - store at 2 to 8C. Antibody without azide - store at -20 to -80 C. Antibody is stable for 24 months. Non-hazardous.
Alternate Names for CD20 Antibody (IGEL/773)
B-lymphocyte antigen CD20
B-lymphocyte cell-surface antigen B1
B-lymphocyte surface antigen B1
Leukocyte surface antigen Leu-16
Membrane-spanning 4-domains subfamily A member 1
membrane-spanning 4-domains, subfamily A, member 1
CD20 is a non-glycosylated phosphoprotein that is expressed on the surface of normal and malignant B cells and functions in mediating calcium transport and B cell differentiation (1,2). CD20 is encoded by the membrane-spanning 4-domain family A member 1 (MS4A1) gene and, in humans, is located on chromosome 11q12 (1). The CD20 protein is 297 amino acids (aa) in length with a theoretical molecular weight (MW) of 33 kDa (1,2). Structurally, the CD20 protein has four membrane-spanning domains, two extracellular loop domains, and intracellular N- and C-terminal domains (1,2). CD20 is expressed at specific stages of B cell maturation including pre-B cells, mature naive and activated B cells, and memory B cells, but is absent from plasmablasts and plasma cells (1,3,4). Expression of CD20 is often increased on malignant B cells associated with various B cell disorders such as chronic lymphocytic leukemia (CLL), multiple sclerosis (MS), and rheumatoid arthritis (2-4). Anti-CD20 monoclonal antibody (mAb)-based therapies have become an appealing target for treating these immune-related disorders and cancers (1-5). Rituximab, a chimeric mAb, was the first FDA approved CD20 monoclonal antibody for the treatment of non-Hodgkin's lymphoma that is now commonly used to treat MS (2,3). Since its initial approval in 1997, several other chimeric and humanized anti-CD20 mAbs have been developed including Ofatumumab, Ublituximab, and Obinutuzumab (1-5). B cell depletion via CD20 mAbs can occur under different mechanisms such as antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), complement-dependent cytotoxicity (CDC), and direct induction of apoptosis (1-4). Many ongoing studies are focused on combination therapies with CD20 mAbs as an addition to chemotherapy, B cell receptor (BCR) signaling inhibitors, or BH3 mimetics (1,2,4). Additionally, the effects of bispecific antibodies and CD20 chimeric antigen receptor (CAR) T cell therapies are under investigation for the treatment of B cell malignancies (4,5).
1. Pavlasova G, Mraz M. The regulation and function of CD20: an "enigma" of B-cell biology and targeted therapy. Haematologica. 2020; 105(6):1494-1506. https://doi.org/10.3324/haematol.2019.243543
2. Payandeh Z, Bahrami AA, Hoseinpoor R, et al. The applications of anti-CD20 antibodies to treat various B cells disorders. Biomed Pharmacother. 2019; 109:2415-2426. https://doi.org/10.1016/j.biopha.2018.11.121
3. Margoni M, Preziosa P, Filippi M, Rocca MA. Anti-CD20 therapies for multiple sclerosis: current status and future perspectives. J Neurol. 2022; 269(3):1316-1334. https://doi.org/10.1007/s00415-021-10744-x
4. Klein C, Jamois C, Nielsen T. Anti-CD20 treatment for B-cell malignancies: current status and future directions. Expert Opin Biol Ther. 2021; 21(2):161-181. https://doi.org/10.1080/14712598.2020.1822318
5. Sharman JP. Targeting CD20: teaching an old dog new tricks. Hematology Am Soc Hematol Educ Program. 2019; 2019(1):273-278. https://doi.org/10.1182/hematology.2019000031
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CD20 Antibody (IGEL/773) and receive a gift card or discount.